Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms CD3 T cell engagers (T-Therapeutics) |
Target |
Action stimulants |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Autoimmune Diseases | Preclinical | United Kingdom | 13 Nov 2025 | |
| Neoplasms | Preclinical | United Kingdom | 13 Nov 2025 |






